UPDATE 2-New York accuses Insys of deceptively marketing opioid

Feb 1 (Reuters) - Insys Therapeutics Inc's legal woes deepened on Thursday as New York's attorney general filed a lawsuit seeking at least $75 million from the company, which he said deceptively promoted a fentanyl-based cancer pain medicine for unsafe uses.